Phoremost logo

PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.


PhoreMost’s first drug discovery program is based on a novel target that addresses the “undruggable” cancer gene KRAS, which affects multiple types of cancer.  This program has recently completed lead optimisation and in vivo anti-tumour activity has been succesfully demonstrated.  PhoreMost is now seeking partners for its further clinical development.